A detailed history of Prelude Capital Management, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 18,778 shares of TERN stock, worth $111,916. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,778
Previous 18,778 -0.0%
Holding current value
$111,916
Previous $156,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $86,375 - $143,737
-13,309 Reduced 41.48%
18,778 $156,000
Q2 2024

Aug 14, 2024

SELL
$4.54 - $8.2 $238,495 - $430,762
-52,532 Reduced 62.08%
32,087 $218,000
Q1 2024

May 15, 2024

BUY
$4.86 - $8.19 $411,248 - $693,029
84,619 New
84,619 $555,000
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $20,467 - $70,266
10,945 New
10,945 $64,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $224M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.